Literature DB >> 9933352

Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism.

J Booij1, G Tissingh, A Winogrodzka, E A van Royen.   

Abstract

Parkinsonism is a feature of a number of neurodegenerative diseases, including Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. The results of post-mortem studies point to dysfunction of the dopaminergic neurotransmitter system in patients with parkinsonism. Nowadays, by using single-photon emission tomography (SPET) and positron emission tomography (PET) it is possible to visualise both the nigrostriatal dopaminergic neurons and the striatal dopamine D2 receptors in vivo. Consequently, SPET and PET imaging of elements of the dopaminergic system can play an important role in the diagnosis of several parkinsonian syndromes. This review concentrates on findings of SPET and PET studies of the dopaminergic neurotransmitter system in various parkinsonian syndromes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933352     DOI: 10.1007/s002590050374

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  38 in total

1.  Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.

Authors:  Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-23       Impact factor: 9.236

2.  [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease.

Authors:  A Winogrodzka; P Bergmans; J Booij; E A van Royen; J C Stoof; E C Wolters
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

3.  Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

Review 4.  SPECT imaging evaluation in movement disorders: far beyond visual assessment.

Authors:  Kosmas Badiavas; Elisavet Molyvda; Ioannis Iakovou; Magdalini Tsolaki; Kyriakos Psarrakos; Nikolaos Karatzas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-02       Impact factor: 9.236

5.  The effect of levodopa therapy on dopamine transporter SPECT imaging with( 123)I-FP-CIT in patients with Parkinson's disease.

Authors:  Orazio Schillaci; Mariangela Pierantozzi; Luca Filippi; Carlo Manni; Livia Brusa; Roberta Danieli; Giorgio Bernardi; Giovanni Simonetti; Paolo Stanzione
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-08       Impact factor: 9.236

6.  Transcranial color-coded sonography helps differentiation between idiopathic Parkinson's disease and vascular parkinsonism.

Authors:  Chung-Fen Tsai; Ruey-Meei Wu; Yu-Weng Huang; Li-Ling Chen; Ping-Keung Yip; Jiann-Shing Jeng
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

7.  Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients.

Authors:  Kathy Dujardin; Luc Defebvre; Alain Duhamel; Pascal Lecouffe; Pascal Rogelet; Marc Steinling; Alain Destée
Journal:  J Neurol       Date:  2004-11       Impact factor: 4.849

8.  Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease.

Authors:  Yu Geng; Guo-hua Shi; Yun Jiang; Ling-xun Xu; Xing-yue Hu; Yu-quan Shao
Journal:  J Zhejiang Univ Sci B       Date:  2005-01       Impact factor: 3.066

9.  Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.

Authors:  Chan-Hyung Kim; Min-Seong Koo; Keun-Ah Cheon; Young-Hoon Ryu; Jong-Doo Lee; Hong-Shick Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

10.  Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging.

Authors:  Deborah Pareto; Albert Cot; Javier Pavía; Carles Falcón; Ignacio Juvells; Francisco Lomeña; Domènec Ros
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.